Background: The systemic injection of neural stem/precursor cells (NPCs) provides remarkable amelioration of the clinicopathological features of experimental autoimmune encephalomyelitis (EAE). This is dependent on the capacity of transplanted NPCs to engage concurrent mechanisms of action within specific microenvironments in vivo. Among a wide range of therapeutic actions alternative to cell replacement, neuroprotective and immune modulatory capacities of transplanted NPCs have been described. However, lacking is a detailed understanding of the mechanisms by which NPCs exert their therapeutic plasticity. This study was designed to identify the first candidate that exemplifies and sustains the immune modulatory capacity of transplanted NPCs.
Introduction
Spontaneous neural tissue repair may occur in acute and/or chronic inflammatory and degenerative disorders of the nervous system such as multiple sclerosis (MS). However, this process is not robust to promote a full functional and stable recovery of the nervous system architecture [1] . Recent advances in (stem) cell biology have raised great expectations that diseases and injuries of the central nervous system (CNS) may be ameliorated by the development and delivery of cell therapies. Though, most (if not all) of the experimental cell therapies described, injecting neural lineage-committed progenitors, have failed to foster substantial tissue repair in disease models where the anatomical and functional damage is widespread and an inflamed and/or degenerative microenvironment co-exists [2] . In contrast, the systemic injection of somatic, and more recently embryonic stem (ES) cell-derived, neural stem/precursor cells (NPCs) has provided remarkable amelioration of the clinico-pathological features of rodents with acute, chronic and relapsing experimental autoimmune encephalomyelitis (EAE), the animal model of MS [3, 4, 5, 6] .
This phenomenon has been shown to be dependent on the capacity of transplanted NPCs to engage multiple mechanisms of action within specific microenvironments in vivo [7] . Among a wide range of potential therapeutic actions, and, in addition to the (expected) cell replacement [3] , remarkable neuroprotective and immune modulatory capacities have been described for transplanted NPCs within specific CNS [3, 4, 5, 6 ] as compared to non-CNS areas [8] . As such, we and others have provided considerable proof that NPC-mediated bystander effects may take place both in the CNS, at the level of the atypical perivascular niches [6] , as well as in secondary lymphoid organs, such as the lymph nodes [8] or the spleen [9] . Nonetheless, following the first report that membranebound Fas/CD90 ligands (e.g., Apo3L, TRAIL and FasL) were regulating part of the NPC-mediated suppressive effect on encephalitogenic T lymphocytes in the CNS [6] , other groups have generated data albeit indirectly that describe the mechanisms responsible for this peculiar somatic stem cell function. In general, this has been supported in studies that utilized in vitro immune cell/ NPC co-cultures [4, 5, 10] , although these studies have provided evidence describing only the short-term in vivo persistence of transplanted NPCs into peripheral (non-CNS) bodily organs [8, 9] . Concurrently, recent reports have begun to elucidate paracrine factors that are responsible for mediating the immune suppressive vs pro-survival capacity of other somatic stem cell sources; these include chemokines and inducible nitric oxide (iNOS) [11] and more recently stanniocalcin-1 (STC-1), a peptide hormone that modulates mineral metabolism [12] . Importantly though, the detailed molecular and cellular mechanism(s) responsible for sustaining the multifaceted therapeutic plasticity exhibited by NPCs in vivo remain far from being fully elucidated, characterized and described.
Herein we report the capacity of NPCs to target, and synergize with immune cells in secondary lymphoid organs (e.g., draning lymph nodes), and have demonstrated this by utilizing a highly peculiar protocol of therapeutic passive NPC vaccination in mice affected by experimental chronic-recurrent autoimmune CNS inflammation. Subcutaneously (s.c.)-injected NPCs accumulate and survive over two months within draining lymph nodes, but not in the CNS, where they stably modify the perivascular lymph node microenvironment. Within this context, surviving NPCs hamper the activation of myeloid dendritic cells (DC) via the release of major developmental stem cell regulators, including the morphogens bone morphogenetic protein (BMP)-4 and sonic hedgehog (Shh), the extracellular matrix protein tenascin C, and the BMP antagonist Noggin.
Nonetheless, we identify a novel BMP-4-dependent mechanism hindering the DC maturation, both in vivo and in vitro. This BMP-dependent effect is highly specific for immune regulatory NPCs, and, in turn, lead to the steady restraint of the expansion of antigen-specific (encephalitogenic) T cells.
Results
Protection of EAE mice upon accumulation of s.c.-injected NPCs into draining lymph nodes SJL mice suffering from relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE), a model of chronicrelapsing autoimmune CNS inflammation leading to demyelination and axonal loss [6] , were injected s.c. into the flanks with subventricular zone (SVZ)-derived syngenic adult NPCs (1.0610 6 cells per mouse). Green fluorescent protein (GFP) + NPCs were injected at either 3 and 10 days post immunization (dpi) with the myelin autoantigen proteolipid protein (PLP)139-151, or at 10 dpi only. Regardless of the timing or number of injections, both groups of NPC-injected R-EAE mice showed significant clinical improvement, as compared to sham-treated controls. Further, mice injected at 10 dpi only, showed a significant delay of disease onset (p#0.005, vs. sham-treated controls). At the end of the follow up period (75 dpi), both groups of NPC-treated mice showed significantly lower R-EAE cumulative score, fewer clinical relapses, and lower burden of spinal cord inflammation (from 46 to 64% reduction), demyelination (from 84 to 98% reduction) and axonal damage (from 89 to 93% reduction), as compared to shamtreated controls. Finally, delayed injection (injected at 30 dpi) of live NPCs or paraformaldehyde (PFA)-fixed NPCs (injected at 10 dpi) did not produce any detectable clinical improvement, as compared to sham-treated controls ( Figure S1 ). The clinico-pathological features of R-EAE mice injected s.c. with different NPC types are summarised in Table 1 and Figure S1 .
To assess quantity, morphology and distribution of s.c.-injected NPCs, a detailed histological analysis was performed at 75 dpi in both the CNS (e.g., brain and spinal cord) and peripheral tissues such as spleen, liver, kidneys and draining lymph nodes from transplanted R-EAE mice. Quite distinct from what occurs upon injection of NPCs either intravenously or intrathecally into EAE rodents after disease onset [3, 6, 13] , we did not find s.c.-injected Data are mean numbers (6SEM) from a total of n = 2 independent experiments. dpi, days post-immunization.
{
The cumulative score represents the summation of each single score recorded for each mouse from the day of immunization (day 0) to day of sacrifice (75 dpi). GFP + cells in the brain, spinal cord, liver, spleen and kidneys. On the other hand, GFP + NPCs were consistently found at both early (e.g., 2 weeks after cell injection) as well as late (e.g., 65-72 days after cell injection) time points in the draining lymph nodes of all NPC-injected R-EAE mice (following both treatment schedules). The number of GFP + cells accumulating and persisting for at 65-72 days after cell injection within draining lymph nodes varied only moderately from case to case. The highest number of GFP + NPCs was observed in axillary and cervical lymph nodes proximal to the cell injection site(s). While the lymph node architecture was preserved and low-power examination did not disclose any alteration, NPCs predominantly accumulated as focal clusters around blood vessels of the hilum and medullary/paracortical areas ( Figure 1A) . The great majority of s.c.-injected NPCs survived long term (greater than 2 months after transplantation) within lymph nodes, while lacking the expression of major antigens of the neural lineage, such as polysialylated neural cell adhesion molecule (PSA-NCAM), class III b-Tubulin, neuronal nucleus Interaction(s) of NPCs and lymph node cells at the level of perivascular areas
In lymph nodes, NPCs established anatomical interaction(s) with von Willebrand factor-immunoreactive endothelial cells ( Figure 1E ) and were identified in close cell-to-cell contact with lymph node cells (LNCs), such as CD11c + dendritic cells (DCs) (Figure 1F ), F4/80 + professional phagocytes ( Figure 1G ) and major histocompatibility complex (MHC) class II + immune cells ( Figure 1H ). While GFP + NPCs and neighbouring LNCs maintained mutually exclusive fluorescence patterns ( Figure 1F and H), only very few phagocytes (5-10% of the total GFP + cells in lymph nodes) were double positive for the GFP and the phagocyte markers F4/80 or CD11b. This suggested that a very low number of s.c.-injected NPCs might have undergone phagocytosis ( Figure 1G and Figure S2 ).
The ultrastructural analysis of lymph nodes from NPC-injected R-EAE mice confirmed the presence of numerous large-size GFP + cells with electrodense grain precipitates displaying morphological and ultrastructural features similar to neurospheres in vitro ( Figure 2 and Figure S3 ). These GFP + cell were rich in organelles, displayed an endoplasmic reticulum with short cisterns and invaginated nucleus with clumped chromatin and were frequently found in close contact with LNCs ( Figure 2A ). Individual GFP + NPCs were found to establish consistent anatomical contacts with LNCs through either polarized microvilli (nanotubes) ( Figure 2B ), cytoplasmic expansions ( Figure 2C ) or elongated intercellular junctions ( Figure 2D ). Transplanted NPCs were also occasionally found in deeper contact and enclosing resident lymph cells, up to membrane fusion ( Figure 2E ), and infrequently, GFP + NPCs showed cytoplasmic vacuoles and picnotic nuclei ( Figure S2 ).
Establishment of ectopic germinal niche-like areas in lymph nodes
We then sought to investigate the molecular features of the lymph node areas appearing as preferential sites of accumulation and, importantly, long term persistence of s.c.-injected NPCs.
Interestingly, lymph nodes from R-EAE mice showed focal high (re)expression of extracellular matrix proteins typical of germinal CNS niches, such as tenascin C [14] , as well as major stem cell regulators, such as BMP-4 and -7 (but not BMP-2) [15, 16] , and Shh [17, 18] (Figure 3A-D) , when compared to lymph nodes from control non-EAE mice. Among these regulators, only BMP-4 ( Figure 3E ), the BMP antagonist Noggin ( Figure 3F ), and Shh ( Figure 3G ) were significantly increased (by 3 to 4-fold) in the axilliary lymph nodes from mice s.c.-injected with NPCs, as compared to sham-treated controls.
We then hypothesised that the establishment of a permissive ectopic germinal niche-like micro-environment in perivascular lymph node areas-molecularly reminiscent of that described in the adult brain upon NPC transplantation [6, 19, 20] -might have allowed the survival, and possibly sustained the function, of s.c.-injected NPCs.
Inhibition of the generation of encephalitogenic T cells
We next investigated whether the observed close vicinity (and interaction) between s.c.-injected NPCs and LNCs within favourable lymph node microenvironments might have had major immunological effects, such as the impairment of the generation of effector (CD4 + ) T cells responsible for the chronic CNS-confined inflammation observed in EAE [21] .
We first found that lymph node T cells from NPC-transplanted R-EAE mice displayed a significantly lower proliferation rate ex vivo in response to PLP139-151, as compared to T cells from sham-treated R-EAE control mice. The same magnitude of unresponsiveness was observed in cervical, axillary and inguinal lymph nodes (p#0.05) ( Figure Quite distinct from what is described for immune regulatory somatic mesenchymal stem cells (MSCs), our findings with NPCs were not paralleled by an increase of T cell apoptosis [24, 25] 
Restrainance of dendritic cell maturation trough soluble bone morphogenetic proteins
The in vivo and in vitro finding that the expansion of antigenspecific effector T cells is hampered in lymph nodes from s.c.-injected R-EAE mice prompted us to speculate a causal impairment of the antigen presentation capacities of professional antigen presenting cells (APC), such as DCs.
Indeed, a significant down-regulation of the co-stimulatory molecules CD80/B7.1 and CD86/B7.2 ( Figure 5A and B), but not MHC class-II, (data not shown) was found ex-vivo on DCs from NPC-treated R-EAE mice, as compared to DCs from shamtreated controls. This latter finding was further confirmed in vitro, as DCs maturating upon exposure to either tumor necrosis factor (TNF)-a or toll-like receptor (TLR) agonists [e.g., poly-IC, lipoteichoic acid (LTA) and bacterial lipopolysaccharide (LPS)] failed to up-regulate CD80/B7.1, CD86/B7.2 and MHC class-II ( Figure 5C -E and Figure S4 ), while producing significantly lowers amounts of pro-inflammatory cytokines, when co-cultured with NPCs ( Figure 5F -G and Figure S4 ). This effect was observed when DCs and NPCs were co-cultured both in the same dish as well as in a trans well co-culture system avoiding cell-to-cell contact ( Figure 5C -G and Figures S4 and S5) .
Interestingly enough, this impairment of the DC maturation was reversible and it could be fixed if the NPCs were removed from the co-culture in vitro system and DCs were put back on maturation with fresh LPS (Figure 6 ).
Therefore, it would be very likely that, at least part of the observed interference with DC maturation may be attributed to NPCs releasing soluble immune-like molecules.
Recent evidence has shown that major developmental factors controlling stem cell fate decisions during vertebrate embryo-genesis and organogenesis-such as the Hedgehog (Hh) family proteins, and the BMPs-2 and -4-also play a role in regulating cell fate and determination in self-renewing tissues in adults, such as the immune system and the haematopoietic system. In one case, the involvement of the Hh signalling has been shown in the negative regulation of the T cell differentiation in the mouse thymus, both in the adult and the foetus [28, 29] . But the other hand, both Shh and BMP-2/-4 have been shown to regulate the development and proliferation of haematopoietic stem cells and the differentiation of mouse thymocytes [29, 30, 31] .
Therefore, the finding that lymph node DCs from R-EAE mice are one of the preferential targets of the major environmental regulators being increased at the level of ectopic germinal niche-like lymph node areas, it is not completely surprising.
As such, DCs are found to express the whole apparatus (e.g., agonists, antagonists, receptors) for being both inducers as well as targets of both BMPs and Shh. Both machineries were also modulated at the mRNA level upon DC activation with LPS ( Figure 7A and B) .
Indeed, BMP-4, but not Shh, was capable of down modulating the membrane expression of CD80/B7.1, CD86/B7.2, and MHC class II molecule, when added in vitro to DCs with LPS ( Figure 7C ). Furthermore, the addition of the BMP antagonist Noggin to both not treated as well as DCs maturating with LPS did not exert any effect ( Figure S6 ). Figure S3 ). The NPC (pseudocolor green) takes contact with four individual lymph node cells (pseudocolor orange). The NPC shows an irregular and invaginated nucleus (n) with a single nucleolus (nu), and its cytoplasm contains abundant organelles; B, Individual GFP + NPCs establishing anatomical contacts with two GFP 2 lymph node cells-one of which (upper right) possesses the morphological characteristics of lymph blasts-through polarized microvilli (boxed area). Note the electrodense grain precipitates within the cytoplasm (arrows) and on the membrane (arrowheads and boxed area); C-E, NPCs in lymph nodes establish cell-to-cell contacts with lymph blasts through cytoplasmic expansions (C) or elongated intercellular junctions (D). Transplanted NPCs are occasionally found in deeper contact and enclosing resident lymph cells (E). Images refer to representative draining lymph nodes from R-EAE mice injected s.c. with NPCs at 3 and 10 dpi. Scale bars in A and B: 2 mm, in C and E: 1 mm, and in D: 500 nm. doi:10.1371/journal.pone.0005959.g002 This BMP-4-dependent effect on DCs resulted in the activation of the mitogen-activated protein kinases (MAPK) p38 and Erk1/2, but not the classical Smad-dependent (data not shown) [32] , intracellular signalling pathways and, again, it was blocked by the addition of Noggin ( Figure 7D ). As additional confirmation of the central role played by BMP-4 in DC function only, we found that Noggin (i) significantly reverted the inhibitory effect of BMP-4 on LPS-induced maturation of DCs ( Figure 7C) ; and, (ii) restored both the expression of co-stimulatory molecules and the capacity to release pro-inflammatory cytokines of DCs co-cultured with NPCs ( Figure S4 ). Moreover, neither BMP-4 nor Shh interfered with the proliferation of CD4 + T lymphocytes stimulated with CD3/CD28 in the absence of APCs ( Figure 7E ). As further functional proof, Noggin reverted the antigen presentation capacity of naive PLP-pulsed DCs co-cultured with NPCs in vitro ( Figure 7F ).
Then, in order to conclusively demonstrate whether the observed immune regulatory effect was indeed specific for NPCs, we challenged the capacity of other somatic stem cells, such as bone marrow derived MSCs and vessel-associated mesoangioblasts (MSAs), of interfering with the expression of co-stimulatory molecules, when co-cultured with DCs maturating in vitro with LPS. Interestingly enough, neither MSCs nor MSAs showed significant inhibitory capacity of the expression of CD80/B7.1 ( Figure 8A ), CD86/B7.2 ( Figure 8B ), and MHC-II ( Figure 8C ) on DCs, as compared to NPCs. More importantly, the addition of the BMP antagonist Noggin was capable to restore the high levels of co-stimulatory molecule expression when DCs were co-cultured with NPCs and the BMP-secreting [33] ATDC5 condrogenic precursor cells only ( Figure 8A-C) .
Discussion
Somatic stem cell-based therapies-including those delivering NPCs-are broadly advised as potential alternative medicines aiming at, in this case brain repair for invalidating CNS diseases. This directive has arisen from the demonstration that NPC-driven clinico-pathological recovery is achieved in several pre-clinical + T cells, while higher percentages IL-4-(x axis in J), IL-10-producing (x axis in K) CD4 + T cells, compared to control LNCs (G, H and I, respectively); M, Adoptive transfer to naive SJL recipients of PLP139-151-specific LNCs having being either co-cultured (LNCs/NPCs, white circles, n = 8 mice) or not (LNCs, black circles, n = 13 mice) with NPCs. Note the significant impairment of EAE development (e.g., delay of the disease onset and reduction of the clinical score), when disease is adoptively transferred with LNCs/NPCs. Data are mean clinical score (6SEM). *p#0.05; **p#0.005. doi:10.1371/journal.pone.0005959.g004 models of neurological disorders [7] . While the replacement of lost/damaged cells was until few years ago assumed as the prime therapeutic mechanism of CNS stem cells [3, 13] , it has now become clear that transplanted somatic stem cells may simultaneously instruct several therapeutic mechanisms amongst which cell replacement, itself, does not prevail. To understand and elucidate the overall therapeutic potential of stem cells in neurological diseases, namely the capacity of stem cells to adapt their fate and function(s) to specific different pathological conditions, we and others have recently proposed the concept of therapeutic plasticity [7] .
The transplantation of different sources of somatic stem cells (e.g. NPCs [3, 4, 6, 13] , haematopoietic stem cells (HSCs) [34, 35] , mesenchymal stem cells (MSCs) [36, 37] ), with very little (if any) capability of neural (trans) differentiation, has promoted diffuse CNS repair via intrinsic neuroprotective bystander capacities. This neuroprotective capability, mainly exerted by undifferentiated stem cells releasing in situ, a milieu of neuroprotective and immunomodulatory molecules, is temporally and spatially orchestrated by environmental needs. Moreover, more recent evidence, including the study herein, has suggested that the majority of the stem cell-mediated therapeutic effects in inflammatory CNS disorders are possibly taking place peripherally, at the level of immune relevant anatomical site, such as secondary lymphoid organs [8, 9, 36 ]. Yet, a current and comprehensive illustration of the different mechanism(s) by which such cells exert their therapeutic potential is lacking.
Herein we report the capacity of NPCs to target, and synergize with immune cells in draining lymph nodes, and have demonstrated this by utilizing a highly peculiar protocol of therapeutic passive (s.c.) NPC vaccination enhancing the capacity of injected NPCs to selectively target the major peripheral sites of immune surveillance (e.g., draining lymph nodes) in mice with EAE [38] .
S.c.-injected NPCs protect mice from chronic CNS-confined autoimmunity via an immune regulatory mechanism that restrains the generation and expansion of pathogenic autoreactive T cells. Regardless of the timing and the number of injections administered, R-EAE mice injected with NPCs before the disease onset showed significant clinical improvement, as compared to shamtreated controls. By contrast, the delayed s.c. injection of NPCs did not produce any detectable clinical improvement, as compared to sham-treated controls. At this juncture, we do not have any clearcut mechanistic explanation in support of the lack of 'treatment effect'. However, based on broad evidence supporting the potential of somatic stem cell-based therapies for the treatment of neurological disorders [7, 39] , is the notion that NPCs exert a broad regulatory capacity, that is dependent on the time of cell injection, and that may be differentially exerted to specifically interact with cells of different microenvironments in vivo [6, 8, 9, 36, 37, 40] .
Further demonstrated is that the therapeutic potential is sustained in vivo by the accumulation, survival and long-term persistence exclusively at the level of secondary lymphoid organs of the transplanted NPCs, which, in turn, modulate the in situ increase of major stem cell fate determinants. In lymph nodes, the increased bioavailability of BMP-4, BMP-7, Shh, and the BMP antagonist Noggin, released by both transplanted NPCs and immune cells, promotes the survival and persistence of s.c.-injected NPCs outside the CNS, at the levels of ectopic perivascular germinal niche-like lymph node areas. This latter is indeed a critical observation. It is in fact well established that somatic stem cells injected systemically in multifocal inflammatory CNS disorders, specifically accumulate and persist for months at the level of inflamed perivascular CNS areas, while promoting recovery [6, 41, 42, 43, 44, 45] . In these areas, named CNS atypical ectopic niches, a molecular cross talk between the transplanted stem cells and CNS cells (e.g., reactive astrocytes, inflamed endothelial cells and blood-borne infiltrating T cells) takes place. The great majority of transplanted stem cells survive within the CNS atypical ectopic niches, while displaying undifferentiated features, owing to the focal release of developmental stem cell regulators by immune cells and CNS resident cells [6] . Also, surviving stem cells promote tissue protection by releasing immunomodulatory and neurotrophic molecules [7] . Therefore, the establishment of atypical ectopic niches upon stem cell therapy, at either the level of the CNS or in peripheral immunologically relevant sites, might be realistically advised as the functional (pre) requisite for the long-term therapeutic activity of transplanted stem cells.
Furthermore, the observed excess of BMP-4 in lymph nodes significantly impaired the maturation and antigen presentation capacities of lymph node DCs, which, in turn, failed to sustain the expansion and full activation of effector (encephalitogenic) T cells. This effect was highly specific for BMP-4, as the BMP antagonist Noggin significantly reverted the inhibitory effect of BMP-4 alone. Interestingly enough, this BMP-4-dependent immune regulatory effect on DCs was also highly specific for NPCs-but not for MSCs or MSAs-as well as completely reversible after the removal of NPCs from the co-cultures.
Our results-along with the recent demonstration that intravenously-injected NPCs suppress T cell proliferation within secondary lymphoid organs [8] -provide additional mechanistic evidence that CNS stem cells can be manipulated to act as immune regulators in promoting CNS repair/protection. This is indeed the first identification of a member of the transforming growth factor (TGF)b/BMP family of stem cell developmental regulators as a novel tolerogenic factor released by immune regulatory NPCs. The phenomenon herein described may be indeed further exploited as an efficient tool for vaccination therapy in autoimmune inflammatory conditions, which result in widespread CNS damage.
Importantly though, our observation follows some very recent reports, which have started identifying some of the first molecular mechanisms responsible for the somatic stem cellmediated regulatory effect on DCs. These have included the demonstration that MSCs affect the DCs function trough the release of (i) IL-6 inhibiting the differentiation to immature DCs [46] , (ii) Notch ligand Jagged-2, which induces the generation of regulatory DCs [47] and, more recently, (iii) prostaglandin E2 inhibiting the differentiation to immature DCs [48] . Therefore, while providing a much deeper molecular view of the therapeutic plasticity of somatic stem cells, these findings and our own data also predict a fairly transversal (inter-disease) significance for most of the somatic stem cell-based approaches aiming at immune regulation.
Critically important is for promoting CNS repair/protection the ongoing study and the elucidation of the role(s) of CNS stem cells in regenerative medicine and it will contribute to the development of more efficacious (stem) cell-based therapies.
Materials and Methods

NPC derivation and cultures
Adult neurospheres were generated from the SVZ of four-toeight week-old SJL mice, as described [6] . Further information is provided as Material S1.
EAE induction and NPC transplantation
Relapsing EAE was induced in a total of n = 112 four-to-eight week-old (weight 20-25 grams) female SJL mice, as described [6] . At time of cell transplantation, single cell-dissociated NPCs were injected sub-cutaneously in both flanks (0.5610 6 cell/ 150 ml PBS in each site). Cell transplants with live NPCs were performed prior to disease onset-at 3 and 10 dpi (n = 35) or 10 dpi only (n = 22) -or after the disease onset, at 30 dpi (n = 10). Paraformaldehyde (PFA)-fixed [5% PFA for 5 minutes at room temperature (r.t.)] NPCs injected s.c. at 10 dpi (n = 10) were use as cellular controls. Sham-treated mice (n = 35) received 0.1 M PBS s.c. (150 ml in each site) at 3 and 10 dpi. All procedures involving animals were performed according to the guidelines of the Animal Ethical Committee of our Institute (IACUC no. 265 to S.P.).Further information is provided as Material S1.
In vitro expansion and adoptive transfer of PLP139-151-specific mouse T cells PLP139-151-specific T cells were obtained from the draining lymph nodes of PLP139-151-immunized SJL mice, at 10 dpi, as described [6] . Further information is provided as Material S1. 
Dendritic cell (DC) preparation and co-cultures
Bone marrow-derived DCs were prepared from flushed tibias and femurs of naive SJL mice (Charles River) and propagated in vitro for 1 week in Iscove's medium (Invitrogen Life Technologies) supplemented with 100 U/ml penicillin (BioWhittaker), 100 mg/ml streptomycin (BioWhittaker), 1.5 mM L-glutamine (BioWhittaker), 10% heat-inactivated foetal calf serum (FCS; EuroClone) and recombinant mouse GM-CSF and IL-4 (both 25 mg/ml, R&D System), as described [49] . In co-cultures, to verify the effect of NPCs on DC maturation, single celldissociated NPCs were added (1:1 NPC/DC ratio) at day 5, either in the same well or in the upper chamber of a 0.4 mm membrane-separated trans-well system (Nunc). Further information is provided as Material S1. PFA-fixed mouse NPCs, NIH3T3 embryonic fibroblasts [50] , mouse mesoangioblasts (MSAs) [51] , bone marrow-derived mouse mesenchymal stem cells (MSCs) [37] and the ATDC5 condrogenic cell line [52] (all 1:1 cell/DC ratio) were used as cellular controls. Further information on MSA, MSC and ATDC5 cell preparations, culture and phenotype is provided as Material S1.
Ex vivo characterization of DC cells from draining lymph nodes
Mice were sacrificed at 7 days post immunization and axillary, cervical and inguinal lymph nodes single-cell suspensions were prepared by pressing the tissue through nylon cell strainer (70 mm, BD Falcon). Cell suspensions were washed with complete media and counted. To analyze CD11c + DC population the following antibodies were used: CD11c (clone HL3), CD86 (clone GL1), CD80 (clone 16-10A1), or MHC class II (clone M5/114.15.2). All antibodies were conjugated to PE or APC and were purchased from BD Biosciences/Pharmingen or Cedarlaine. For the analysis of cell surface protein expression, 1,5610 6 lymph node cells were stained with the antibodies above for 15 min at room temperature in presence of 2 mg/ml of mouse IgG as FcR blocking reagent. Cells were then washed in PBS and just before analysis on a FACSCanto TM (Becton Dickinson). 7-Amino-actinomycin D (7-AAD) was added for dead cell exclusion. A maximum of 5,000 events into the gate of CD11c cells were acquired for each sample. Data were analyzed using FCS Express V3 (De Novo Software).
RT-PCR
Real-time quantitative PCR was performed using pre-developed Taqman TM Assay Reagents on an ABI Prism TM 7700 Sequence Detection System (Applied Biosystems) according to manufacturers protocol. Further information is provided as Material S1.
Western blot analysis
Western blot analysis of BMP-4, Noggin and Shh was performed using surgically dissected pairs of cervical and axillary lymph nodes from naive SJL mice and both sham-and NPCtreated R-EAE mice. Analysis of ERK1/2, phospho ERK1/2, p38, phospho p38, SMAD 1 and phospho-SMAD1/5/8 proteins expression was performed using not treated and LPS-treated DCs. Further information is provided as Material S1.
Cytokine assay
Supernatants from DC/NPC co-colture experiments were collected and cytokine production was analyzed with the Bioplex Protein Array system (BioRad) using fluorescent beads specific for mouse IL-1a, IL-2, IL-4, IL-10, IL-12 (p70), IFN-c, TNF-a, IL-15, IL-18 and M-CSF, according to the manufacturer instructions as described [53] . Samples were analysed in quadruplicate, and fluorescence was read with the Luminex system (Biorad). Bio-plex manager 4.0 software (Biorad) was used for the analysis of data. 
FACS analysis
Tissue pathology
At sacrifice mice were trans-cardially perfused with 4% paraformaldehyde and CNS tissue (brain and spinal cord), liver, spleen, kidneys and cervical, inguinal, axillary, mesenteric and paraortic lymph nodes were removed and processed for pathology on either paraffin-embedded or frozen tissue samples, as described [6] . The complete list of antibodies used and further information is provided as Material S1.
Immunogold and electron microscopy
At sacrifice, mice were perfused transcardially with 0.9% saline, followed by 4% paraformaldehyde. The lymph nodes were removed and post-fixed in the same fixative overnight. Further information is provided as Material S1.
Histochemistry
Further information is provided as Material S1.
Statistical analysis
Data were compared using the Student's t-test for paired or unpaired data, the one-way Anova test or the Mann-Whitney Utest for non-parametric data. 
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